Pfizer to acquire migraine firm for over USD 11bn

US-based Pfizer is prepared to pay as much as USD 11.6bn to buy Biohaven Pharmaceuticals and its approved migraine therapy.

Photo: Dado Ruvic/REUTERS / X02714

On Tuesday, Pfizer has announced its intention to acquire Biohaven Pharmaceuticals, agreeing to pay USD 148.5 per share in cash, which equals to a whopping price tag of USD 11.6bn, a company press release reports.

Pfizer became a household name during the pandemic, when the firm, alongside German Biontech, developed a vaccine against Covid-19.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs